 |
|
Maximum: 1 CME cr.
Sign in to view your progression
|
The present educational case study aims to offer practicing urologists an in-depth look at advanced imaging modalities for the management of NMIBC using a patient case example.
Upon completion of this educational activity, the participant should be able to:
· Demonstrate an understanding of the epidemiology, health care costs, and impact on patient quality of life of NMIBC
· Identify the tools available for diagnosis of NMIBC
· Describe the unresolved issues associated with NMIBC
· Describe the various imaging modalities available for use in diagnosing NMIBC, including new developments in imaging and their advantages and disadvantages
· Discuss the potential impact of new imaging modalities on the treatment of NMIBC
This programme is designed for urologists around the world who are SIU members or SIU Academy-registered members.
CHAIR
Théo de Reijke, MD, PhD, FEBU
Urologist, Department of Urology
Academic Medical Center
Amsterdam, The Netherlands
Disclosures: Dr. de Reijke has no conflicts of interest to disclose.
SCIENTIFIC COMMITTEE MEMBERS
Ashish M. Kamat, MD, MBBS, FACS
Professor of Urology
Director of Urologic Oncology Fellowship
The University of Texas, MD Anderson Cancer Center
Houston, Texas, United States of America
Disclosures:
Clinical trials: FKD, Heat Biologics, Bioniche (Telesta Therapeutics)
Merck, Photocure, Abbott, Sanofi, Theralase, Bioniche
Badrinath R. Konety, MD, MBA
Professor and Chair
Dept of Urology
Dougherty Family Chair in Uro-Oncology
Associate Director for Clinical Affairs
Masonic Cancer Center
University of Minnesota
Minneapolis, Minnesota, United States of America
Disclosures:
Clinical trials: Photocure, Genomic Health, Myriad Genetics
Rafael Sanchez-Salas, MD
Staff Surgeon, Department of Urology
Institut Montsouris
Paris, France
Disclosures: Olympus, Histoscanning, EDAP, Intuitive Surgical, École Européenne de Chirurgie
Arnulf Stenzl, MD
Professor and Chairman
Department of Urology
Eberhard-Karls-University
Tuebingen, Germany
Disclosures:
Current: Ad Board /Consultant: Ipsen Pharma, Janssen, Alere
Speaker: Janssen, Ipsen Pharma
Institution
Clinical study, Johnson & Johnson, Bayer AG, CureVac, Immatics Biotechnologies GmbH
Research grant, Amgen Inc., Immatics biotechnologies GmbH, Novartis AG, Karl Storz AG
Past
Ad Board /Consultant: Novartis
Clinical study: Johnson & Johnson, Photocure ASA
Research grant: Storz Medical
|
Step 1 : Background Knowledge Assessment
|
|
|
AIM for NMIBC: Advanced Imaging Modalities for Non-Muscle Invasive Bladder Cancer
|
|
